One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity

被引：17

作者：

Hertz, Daniel L. ^{[1
]}

Rae, James M. ^{[2
]}

机构：

[1] Univ Michigan, Coll Pharm, Dept Clin Pharm, 428 Church St, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Div Hematol Oncol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

来源：

PHARMACOGENOMICS | 2016年 / 17卷 / 08期

关键词：

clinical utility; clinical validity; CYP2D6; endoxifen; estrogen receptor positive breast cancer; tamoxifen; BREAST-CANCER; ACTIVITY SCORE; GENOTYPE; METABOLISM; WOMEN; RECURRENCE; EXPOSURE; PATIENT;

D O I：

10.2217/pgs-2016-0059

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：823 / 826

页数：4

共 23 条

[1] Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: Clinical implications [J].

Bernard, Stephen ;

Neville, Kathleen A. ;

Nguyen, Anne T. ;

Flockhart, David A. .

ONCOLOGIST, 2006, 11 (02) :126-135

[2] CYP2D6 Genotype and Adjuvant Tamoxifen [J].

Berry, D. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) :138-140

[3] Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients [J].

Borges, Silvana ;

Desta, Zeruesenay ;

Jin, Yan ;

Faouzi, Azzouz ;

Robarge, Jason D. ;

Philip, Santosh ;

Nguyen, Anne ;

Stearns, Vered ;

Hayes, Daniel ;

Rae, James M. ;

Skaar, Todd C. ;

Flockhart, David A. ;

Li, Lang .

JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04) :450-458

[4] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J].

Davies, C. ;

Godwin, J. ;

Gray, R. ;

Clarke, M. ;

Darby, S. ;

McGale, P. ;

Wang, Y. C. ;

Peto, R. ;

Pan, H. C. ;

Cutter, D. ;

Taylor, C. ;

Ingle, J. .

LANCET, 2011, 378 (9793) :771-784

[5]

Dean L., 2014, Medical Genetics Summaries

[6] CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects [J].

Dezentje, V. O. ;

Opdam, F. L. ;

Gelderblom, H. ;

den Hartigh, J. ;

Van der Straaten, T. ;

Vree, R. ;

Maartense, E. ;

Smorenburg, C. H. ;

Putter, H. ;

Dieudonne, A. S. ;

Neven, P. ;

Van de Velde, C. J. H. ;

Nortier, J. W. R. ;

Guchelaar, H. -J. .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) :583-590

[7] The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype [J].

Gaedigk, A. ;

Simon, S. D. ;

Pearce, R. E. ;

Bradford, L. D. ;

Kennedy, M. J. ;

Leeder, J. S. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :234-242

[8] CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8 [J].

Goetz, Matthew P. ;

Suman, Vera J. ;

Hoskin, Tanya L. ;

Gnant, Michael ;

Filipits, Martin ;

Safgren, Stephanie L. ;

Kuffel, Mary ;

Jakesz, Raimund ;

Rudas, Margaretha ;

Greil, Richard ;

Dietze, Otto ;

Lang, Alois ;

Offner, Felix ;

Reynolds, Carol A. ;

Weinshilboum, Richard M. ;

Ames, Matthew M. ;

Ingle, James N. .

CLINICAL CANCER RESEARCH, 2013, 19 (02) :500-507

[9]

Haque R, 2016, J NATL CANC I, V108

[10] Integrated patient and tumor genetic testing for individualized cancer therapy [J].

Hertz, D. L. ;

McLeod, H. L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) :143-146

← 1 2 3 →